Id: acc1759
Group: 2sens
Protein: FAK
Gene Symbol: PTK2
Protein Id: Q05397
Protein Name: FAK1_HUMAN
PTM: phosphorylation
Site: Tyr925
Site Sequence: NLDRSNDKVYENVTGLVKAVI
Disease Category: Cancer
Disease: Meningioma
Disease Subtype:
Disease Cellline: CH-157MN
Disease Info:
Drug: pUC
Drug Info: -
Effect: modulate
Effect Info: "The phosphorylation level of FAK (at the Y925 site) in the pUC treatment group was significantly reduced, inhibiting tumor angiogenesis."
Note:
Score: 4.0
Pubmed(PMID): 21347260
Sentence Index:
Sentence:

Sequence & Structure:

MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 3 Recruiting ovarian cancer ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Terminated malignant pleural mesothelioma ClinicalTrials
ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Active, not recruiting multiple myeloma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting pancreatic carcinoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting thyroid carcinoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Active, not recruiting ovarian serous adenocarcinoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting pancreatic adenocarcinoma ClinicalTrials
PTK2 GSK-2256098 Focal adhesion kinase 1 inhibitor 2 Completed pancreatic adenocarcinoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Active, not recruiting Uveal Melanoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting pancreatic ductal adenocarcinoma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Not yet recruiting colorectal cancer ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Active, not recruiting ovarian cancer ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting ovarian cancer ClinicalTrials
PTK2 IFEBEMTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting ovarian cancer ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Completed lung cancer ClinicalTrials
PTK2 GSK-2256098 Focal adhesion kinase 1 inhibitor 2 Recruiting meningioma ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 2 Recruiting female reproductive system neoplasm ClinicalTrials
PTK2 GSK-2256098 Focal adhesion kinase 1 inhibitor 2 Recruiting intracranial meningioma ClinicalTrials
PTK2 VS-4718 Focal adhesion kinase 1 inhibitor 1 Withdrawn B-cell acute lymphoblastic leukemia ClinicalTrials
PTK2 VS-4718 Focal adhesion kinase 1 inhibitor 1 Withdrawn acute myeloid leukemia ClinicalTrials
PTK2 DEFACTINIB Focal adhesion kinase 1 inhibitor 1 Active, not recruiting endometrioid carcinoma ClinicalTrials
PTK2 IFEBEMTINIB Focal adhesion kinase 1 inhibitor 1 Not yet recruiting neoplasm ClinicalTrials
PTK2 IFEBEMTINIB Focal adhesion kinase 1 inhibitor 1 Recruiting neoplasm ClinicalTrials
ClinicalTrials
PTK2 CEP-37440 Focal adhesion kinase 1 inhibitor 1 Completed neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
PTK2-Tyr925
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.981
GBM 0.023
HNSC
LUAD 0.293
LUSC 0.993
non_ccRCC 0.192
PDAC -1.892
UCEC -0.59

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 925 D Colon cancer/carcinoma Phosphorylation 15958584
Y 925 U Pancreatic ductal adenocarcinoma Phosphorylation 35982848
Y 925 U Prostate cancer Phosphorylation 35682554

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: